State Street Corp Increases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

State Street Corp grew its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 12.3% during the 3rd quarter, Holdings Channel reports. The fund owned 214,883 shares of the company’s stock after buying an additional 23,564 shares during the period. State Street Corp’s holdings in Jasper Therapeutics were worth $4,042,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of JSPR. Samsara BioCapital LLC increased its stake in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares in the last quarter. Braidwell LP bought a new stake in Jasper Therapeutics during the third quarter valued at about $9,091,000. Verition Fund Management LLC purchased a new stake in Jasper Therapeutics in the third quarter worth about $477,000. Ally Bridge Group NY LLC raised its stake in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares during the period. Finally, MetLife Investment Management LLC lifted its position in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JSPR. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday, December 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Stock Down 5.8 %

JSPR opened at $20.95 on Tuesday. The company has a market capitalization of $314.27 million, a PE ratio of -4.42 and a beta of 2.18. The firm has a 50-day simple moving average of $21.97 and a two-hundred day simple moving average of $20.61. Jasper Therapeutics, Inc. has a 52 week low of $6.41 and a 52 week high of $31.01.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.